Mar 05, 2020
Addyi Demonstrates Significant Improvements in Female Sexual Function for Arousal, Desire, Lubrication, Satisfaction, and Orgasm
Feb 12, 2020
3 in 5 men in US Affected by Erectile Dysfunction - and Most Are Unaware It Can Be an Indicator of More Serious Health Problems
Oct 16, 2019
Vyleesi(TM) Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress
Sep 13, 2019
LoveThrob.com is the World's 1st Automated Solution for Sexless Marriages
Sep 09, 2019
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market to 2027: Affordable Reimbursement Scenario for Pharmacotherapy Employed in the Treatment of HSDD
Sep 04, 2019
FDA Removes Alcohol Ban with Addyi - the First-and-Only Non-Hormonal Treatment for Hypoactive (Low) Sexual Desire Disorder (HSDD)
Aug 29, 2019
BioPlus Specialty Pharmacy in Semi-Exclusive Relationship to Dispense Vyleesi(TM) (Bremelanotide Injection)
Jun 21, 2019
FDA Approves New Drug Application for Vyleesi(TM) (bremelanotide injection)
Apr 23, 2019
The erectile dysfunction (ED) drugs market will register a CAGR of over 4% by 2023
Jan 31, 2019
Global Erectile Dysfunction API Manufacturers, Marketed and Phase III Drugs Landscape 2019 - Forecast Sales to 2021
Jan 10, 2019
Best-Selling Author, Dr. Michael Ruscio, Reveals Why Soundwaves Are Vital in Helping Men Maintain Erectile Optimization
Jan 04, 2019
S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys(TM) for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting
Oct 26, 2018
Global Erectile Dysfunction Market and Competitive Landscape Overview 2018
Sep 11, 2018
See Dr. Emily Porter on KXAN TV's Studio 512 With A Non-Drug Treatment, GAINSWave, For Erectile Dysfunction!
Aug 31, 2018
CardioVascular BioTherapeutics, Inc. Appoints Dr. David M. Ornitz and Dr. Arnold I. Chin to its Scientific and Medical Advisory Board
Jun 27, 2018
Pivot Pharma To File Investigational New Drug (IND) Application With U.S. FDA For PVT-005
Jun 04, 2018
Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA
Mar 26, 2018
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
Mar 12, 2018
Mayo Clinic Proceedings Publishes First Consensus Clinical Management of HSDD in Women Authored by ISSWSH
Nov 16, 2017
Global Erectile Dysfunction Epidemiology and Patient Flow Analysis - 2017